6 completed, 2 not yet recruiting, 1 active not recruiting. 9 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Not yet recruiting 2, Active not recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Moderate to Severe Plaque Psoriasis: new trials by email Literature Review of Moderate to Severe Plaque Psoriasis trials Research Report on Moderate to Severe Plaque Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study of HS-20118 to Evaluate the Efficacy and Safety in Participant With Moderate-to-Severe Plaque Psoriasis HS-20118, Placebo - Moderate to Severe Plaque Psoriasis | Phase 2 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 120 | 2026-08-06 | 2026-08-14 |
| A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis CMS-D001 50mg, CMS-D001 100mg, Placebo - Moderate to Severe Plaque Psoriasis | Phase 2 / Phase 3 | Not yet recruiting | Dermavon Holdings Limited | 540 | 2026-03-03 | 2026-02-25 |
| A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis SHR-1139 Injection, SHR-1139 Injection Placebo - Moderate to Severe Plaque Psoriasis | Phase 2 | Active not recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 145 | 2025-03-28 | 2025-07-14 |
| Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis ICP-488 Tablets, ICP-488 Placebo - Moderate to Severe Plaque Psoriasis | Phase 2 | Completed | Beijing InnoCare Pharma Tech Co., Ltd. | 129 | 2024-01-04 | 2025-02-28 |
| Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis NDI-034858 study drug, Placebo - Moderate to Severe Plaque Psoriasis | Phase 2 | Completed | Takeda | 259 | 2021-08-11 | 2023-09-28 |
| A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis bimekizumab - Moderate to Severe Plaque Psoriasis | Phase 2 | Completed | UCB Biopharma SRL | 41 | 2021-04-06 | 2026-08-03 |
| To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis Placebo, SCD-044_Low Dose (Dose 1), SCD-044_Intermediate Dose (Dose 2) - Moderate to Severe Plaque Psoriasis | Phase 2 | Completed | Sun Pharmaceutical Industries Limited | 263 | 2021-03-25 | 2026-01-20 |
| A Phase 2 Clinical Study of KHK4827 KHK4827, Placebo - Moderate to Severe Plaque Psoriasis | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 140 | 2012-12-01 | 2013-09-05 |
| Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis IMO-3100 at 0.16 mg/kg, Saline for Injection, IMO-3100 at 0.32 mg/kg - Actively Extending Plaque Psoriasis, Moderate to Severe Plaque Psoriasis | Phase 2 | Completed | Idera Pharmaceuticals, Inc. | 44 | 2012-05-01 | 2018-01-09 |
Psoriasis (2)
Skin Diseases (2) · Skin Diseases, Papulosquamous (2) · Skin and Connective Tissue Diseases (2)
Injections (1) · Sodium Chloride (1) · bimekizumab (1) · brodalumab (1)
Beijing InnoCare Pharma Tech Co., Ltd. (1) · Dermavon Holdings Limited (1) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · Idera Pharmaceuticals, Inc. (1) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1) · Kyowa Kirin Co., Ltd. (1) · Sun Pharmaceutical Industries Limited (1) · Takeda (1) · UCB Biopharma SRL (1)
United States (4) · China (3) · Canada (2) · Poland (2) · El Salvador (1) · Estonia (1) · Georgia (1) · Germany (1) · Japan (1)
PMID 26547109, PMID 39167366, PMID 42143206
2023 (1)